Quality of Life for Respiratory Illness Questionnaire

1. Abstract

The Quality of Life for Respiratory Illness Questionnaire (QoLRIQ) is a disease-specific psychometric instrument developed by Albert R. Maillé and colleagues in 1997 to evaluate health-related quality of life (HRQoL) in adult and elderly patients diagnosed with chronic obstructive pulmonary disease (COPD) and bronchial asthma. Chronic respiratory conditions exert multifaceted systemic burdens extending far beyond physiological airway obstruction, profoundly compromising emotional stability, physical functioning, functional independence, and interpersonal relations. Comprising 55 items distributed across seven conceptually and empirically validated domains, the instrument captures: (1) Breathing Problems (9 items), (2) Physical Problems (9 items), (3) Emotions (9 items), (4) Situations Triggering or Worsening Breathing Problems (7 items), (5) General Activities (7 items), (6) Daily and Domestic Activities (6 items), and (7) Social Activities, Relationships, and Sexuality (8 items).

Each item is evaluated along a standardized 7-point Likert scale ranging from 1 (“Not troubled at all / Not at all”) to 7 (“Extremely troubled / All the time”). Subscale and total composite scores are calculated as the arithmetic mean of completed items, with higher scores quantitatively indexing greater functional impairment and decrements in subjective quality of life. Extensive psychometric evaluations demonstrate high internal consistency across subscales (Cronbach’s alpha ranging from .73 to .92; total scale α > .95) and robust test-retest reliability intraclass correlation coefficients (ICCs between .78 and .91). Construct, convergent, and discriminant validity have been confirmed via systematic associations with clinical indices such as forced expiratory volume in one second (FEV1), the St. George’s Respiratory Questionnaire (SGRQ), the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36), and hospital anxiety and depression markers. The QoLRIQ remains an essential clinical trials endpoint and clinical practice assessment tool internationally.

2. Keywords

Quality of Life for Respiratory Illness Questionnaire, QoLRIQ, health-related quality of life, asthma, chronic obstructive pulmonary disease, COPD, patient-reported outcome measures, psychometrics, respiratory disease, functional status

3. Authors

The primary architect of the Quality of Life for Respiratory Illness Questionnaire is Dr. Albert R. Maillé, who conducted foundational psychometric and clinical validation research in the Department of General Practice and Department of Pulmonology at Leiden University Medical Center (LUMC) in the Netherlands, in close collaboration with the Netherlands Institute for Health Services Research (NIVEL). Co-investigators and key contributors to the psychometric development and clinical trials implementation of the instrument include:

• Albert R. Maillé, PhD – Department of General Practice, Leiden University Medical Center, Leiden, the Netherlands; NIVEL (Netherlands Institute for Health Services Research), Utrecht, the Netherlands.
• A. A. Kaptein, PhD – Professor of Medical Psychology, Unit of Psychology, Leiden University Medical Center, Leiden, the Netherlands.
• P. J. Sterk, MD, PhD – Department of Pulmonology, Leiden University Medical Center, Leiden, the Netherlands.
• A. M. J. Wever, MD, PhD – Department of Respiratory Medicine, Medisch Centrum Haaglanden, The Hague, the Netherlands.
• J. Hermans, PhD – Department of Medical Statistics, Leiden University Medical Center, Leiden, the Netherlands.

4. Purpose

The fundamental purpose of the Quality of Life for Respiratory Illness Questionnaire (QoLRIQ) is to provide an empirically grounded, clinically responsive, and disease-specific patient-reported outcome measure (PROM) tailored specifically to the systemic demands of asthma and COPD. While generic HRQoL instruments such as the SF-36 or EuroQol-5D (EQ-5D) capture broad health domains, they frequently lack sensitivity to the unique triggers, acute paroxysmal events, environmental reactivities, and intimate psychological stressors typical of obstructive respiratory illness. Conversely, purely physiological measures, including spirometric indices like Forced Expiratory Volume in 1 second (FEV₁), peak expiratory flow (PEF) variation, and arterial blood gas values, consistently correlate poorly with a patient’s daily functional capacity, psychological distress, and perceived handicap.

The QoLRIQ addresses this clinical-scientific disconnect by measuring the functional consequences of illness through the patient’s subjective appraisal. In clinical trials, it acts as a primary or secondary efficacy endpoint, quantifying how pharmacological regimens (such as inhaled corticosteroids, long-acting β₂-agonists, or biologic therapies) or non-pharmacological interventions (such as pulmonary rehabilitation and cognitive-behavioral stress management) alleviate real-world impairment. In outpatient clinical practice, the tool offers pulmonary physicians, respiratory nurses, and general practitioners a comprehensive, multidimensional profile of patient vulnerability, facilitating personalized disease management that extends beyond airway mechanics to target social withdrawal, environmental vulnerabilities, and emotional comorbidities.

5. Psychological Construct

The construct assessed by the QoLRIQ is multidimensional health-related quality of life (HRQoL) within chronic obstructive lung disease. Rather than treating functional limitation as a unidimensional deficit, the QoLRIQ measures HRQoL across seven operationalized sub-domains:

• Breathing Problems (Items 1–9): Captures core respiratory symptoms and their nocturnal/diurnal manifestations, including resting dyspnea, exertional breathlessness, cough, wheeze, excessive sputum production, chest tightness, unpredictable acute exacerbations, and nocturnal sleep interruptions caused by respiratory distress.
• Physical Problems (Items 10–18): Focuses on generalized somatic sequelae, systemic physical fatigue, somatic exhaustion, musculoskeletal stiffness, physical deconditioning, secondary autonomic or medication side effects (such as dry mouth and hoarseness from inhalers), and postural instability or dizziness.
• Emotions (Items 19–27): Assesses psychological distress, affective disturbance, panic reactions associated with breathlessness, free-floating anxiety, frustration with physiological constraints, existential worry regarding disease trajectory, perceived dependency on pharmaceutical agents, and reliance on informal caregivers.
• Situations Triggering or Worsening Breathing Problems (Items 28–34): Evaluates perceived environmental vulnerability and hyperreactivity, detailing the degree to which weather shifts, humidity, industrial pollutants, cigarette smoke, volatile organic compounds, pollen, acute viral respiratory infections, and interpersonal emotional stressors trigger symptomatic deterioration.
• General Activities (Items 35–41): Quantifies gross motor limitations, including outdoor ambulation, climbing inclines or staircases, lifting loads, engaging in recreational sports, coping with temporal urgency, and performing actions requiring torso flexion or kneeling.
• Daily and Domestic Activities (Items 42–47): Measures micro-level functional autonomy, encompassing routine domestic chores (dusting, dishwashing), heavy housework (vacuuming, laundering), meal preparation, personal hygiene routines (bathing, dressing), and self-directed domestic maintenance.
• Social Activities, Relationships, and Sexuality (Items 48–55): Addresses interpersonal functioning, including social participation, entertaining visitors, entering crowded public venues, pursuing leisure activities, interpersonal communication barriers, relational strains, and sexual intimacy disruptions.

6. Theoretical Framework

The conceptual architecture of the QoLRIQ rests upon the Biopsychosocial Model (Engel, 1977) and the Common Sense Model of Self-Regulation of Health and Illness (Leventhal et al., 1980). Engel’s paradigm posits that disease pathology cannot be meaningfully separated from psychological state and sociocultural context. Biological airway remodeling and inflammation interact continuously with subjective cognition, affective distress, and social engagement patterns.

Under Leventhal’s Self-Regulation framework, individuals form cognitive and emotional representations of their illness, encompassing identity (symptoms), timeline (chronic vs. episodic), consequences (functional restrictions), and cure/controllability. When patients experience dyspneic crises, the subjective cognitive appraisal of breathlessness as an existential threat rapidly generates panic, which exacerbates hyperventilation and dynamic hyperinflation. This dyspnea-anxiety-avoidance cycle leads patients to avoid physical exertion and social interaction to prevent breathlessness. The QoLRIQ systematically evaluates this regulatory cycle across its behavioral, affective, and somatic dimensions.

7. Validity

The construct, convergent, discriminant, and predictive validity of the QoLRIQ have been thoroughly established across primary care, tertiary pulmonary clinics, and international cohorts:

• Convergent Validity: Strong and statistically significant correlations have been documented between QoLRIQ domain scores and parallel constructs in established inventories. The QoLRIQ Breathing Problems and Physical Problems subscales correlate strongly with the St. George’s Respiratory Questionnaire (SGRQ) Symptoms and Activity scores ($r = .68$ to $.81$, $p < .001$) and the SF-36 Physical Functioning domain ($r = -.62$ to $-.74$, $p < .001$). The Emotions subscale correlates robustly with the Hospital Anxiety and Depression Scale (HADS; $r = .65$ to $.73$ for anxiety and depression subscales).
• Discriminant Validity: The QoLRIQ discriminates effectively between differing stages of disease severity classified according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria and Global Initiative for Asthma (GINA) guidelines. Significant stepwise score increases are observed across mild, moderate, and severe classifications ($F > 18.4$, $p < .001$). Furthermore, the instrument displays divergent validity by maintaining low-to-moderate correlations with non-respiratory somatic complaints.
• Predictive & Longitudinal Validity: Longitudinal validation demonstrates that the QoLRIQ is sensitive to therapeutic change following pulmonary rehabilitation regimens, smoking cessation interventions, and stepped-up pharmacotherapy. Standardized response means (SRM) following multi-week pulmonary rehabilitation programs range from $0.52$ to $0.88$, indicating moderate to large responsiveness.

8. Reliability

The psychometric reliability of the QoLRIQ has been demonstrated across multiple clinical studies:

• Internal Consistency: Cronbach’s alpha coefficients across all seven subscales consistently exceed the conventional psychometric threshold of $.70$ for research and $.80$ for clinical monitoring. Published validation studies report the following internal consistency values:
  • Breathing Problems: $\alpha = .84 – .89$
  • Physical Problems: $\alpha = .80 – .85$
  • Emotions: $\alpha = .86 – .92$
  • Situations Triggering/Worsening Problems: $\alpha = .78 – .83$
  • General Activities: $\alpha = .82 – .88$
  • Daily and Domestic Activities: $\alpha = .79 – .86$
  • Social Activities, Relationships, and Sexuality: $\alpha = .81 – .88$
  • Total QoLRIQ Score: $\alpha = .95 – .97$
• Test-Retest Reliability: Intraclass correlation coefficients (ICCs) evaluated over 2-week to 4-week intervals in clinically stable patients demonstrate high stability, with domain ICCs ranging from $.78$ to $.91$ and total score ICCs reaching $.92$.

9. Factor Analysis

The structural dimensionality of the QoLRIQ was originally established via exploratory factor analysis (EFA) with oblimin oblique rotation, reflecting the expected inter-correlations among quality of life domains. EFA demonstrated a clear 7-factor solution explaining over 61% of total variance, with item factor loadings predominantly exceeding $.45$ on their designated primary factors and negligible cross-loadings (< $.25).

Subsequent confirmatory factor analyses (CFA) on independent clinical cohorts have supported the empirical defensibility of this 7-factor model. Goodness-of-fit indices for the correlated 7-factor model demonstrate acceptable to good structural fit (Comparative Fit Index [CFI] = $.92–.94; Tucker-Lewis Index [TLI] =$.91–.93; Root Mean Square Error of Approximation [RMSEA] = $.048–.056, 90% CI [.044, .060]; Standardized Root Mean Square Residual [SRMR] =$.052). Second-order CFA models also validate a single overarching latent construct of Respiratory-Specific HRQoL subsuming the seven primary factors.

10. Instrument / Measurement Tool

• Test Type: Disease-specific Patient-Reported Outcome Measure (PROM); health-related quality of life self-administered questionnaire.
• Format: Paper-and-pencil or validated electronic patient-reported outcome (ePRO) digital survey.
• Item Count: 55 standardized items.
• Target Population: Adult and elderly individuals (≥ 18 years of age) with verified diagnoses of asthma or chronic obstructive pulmonary disease (COPD).
• Administration Time: Approximately 12 to 18 minutes.
• Response Scale: 7-point Likert scale (1 = Not troubled at all / Not at all, 7 = Extremely troubled / All the time).
• Scoring Protocol:
  • Subscale scores for each of the 7 domains are computed by taking the arithmetic mean of the completed items within that domain.
  • The Total QoLRIQ score is calculated as the grand mean across all 55 items (or the mean of the 7 domain scores).
  • Scores range continuously from 1.0 to 7.0.
  • Directionality: Higher scores indicate greater functional impairment, higher symptom burden, and poorer health-related quality of life.

11. Permissions & Fee and Test Year

The Quality of Life for Respiratory Illness Questionnaire (QoLRIQ) was developed and published in 1997 by Dr. Albert R. Maillé and collaborators at Leiden University Medical Center (LUMC) and NIVEL. The instrument is protected by international academic copyright.

For non-commercial clinical research, academic thesis work, and routine patient care within public healthcare environments, the instrument is generally accessible without royalty fees, subject to formal registration and permission from the primary copyright holders or originating institutions. Commercial entities, including pharmaceutical companies, clinical trials management organizations (CROs), and proprietary medical software developers, are required to secure a formal licensing agreement and pay associated administrative fees prior to deployment.

12. References

• Engel, G. L. (1977). The need for a new medical model: A challenge for biomedicine. Science, 196(4286), 129–136. https://doi.org/10.1126/science.847460
• Jones, P. W., Quirk, F. H., Baveystock, C. M., & Littlejohns, P. (1992). A self-complete measure of health status for chronic airflow limitation: The St. George’s Respiratory Questionnaire. American Review of Respiratory Disease, 145(6), 1321–1327. https://doi.org/10.1164/ajrccm/145.6.1321
• Leventhal, H., Meyer, D., & Nerenz, D. (1980). The common sense representation of illness danger. In S. Rachman (Ed.), Contributions to Medical Psychology (Vol. 2, pp. 7–30). Pergamon Press.
• Maillé, A. R. (1997). Quality of life in asthma and COPD: Development and validation of the Quality of Life for Respiratory Illness Questionnaire (QoLRIQ) (Doctoral dissertation). Leiden University Medical Center, Leiden, the Netherlands.
• Maillé, A. R., Kaptein, A. A., Koning, C. J., Zwinderman, A. H., & Sterk, P. J. (1994). Developing a quality-of-life questionnaire for patients with respiratory illness: The Quality of Life for Respiratory Illness Questionnaire (QoLRIQ). European Respiratory Journal, 7(Suppl 18), 441s.
• Maillé, A. R., Koning, C. J., Zwinderman, A. H., Willems, L. N., Dijkman, J. H., & Kaptein, A. A. (1996). The development of the ‘Quality of Life for Respiratory Illness Questionnaire’ (QoLRIQ): A disease-specific quality-of-life questionnaire for patients with mild to moderate chronic non-specific lung disease. Quality of Life Research, 5(2), 297–311. https://doi.org/10.1007/BF00434751
• Ware, J. E., Jr., & Sherbourne, C. D. (1992). The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Medical Care, 30(6), 473–483. https://doi.org/10.1097/00005650-199206000-00002
• Zigmond, A. S., & Snaith, R. P. (1983). The Hospital Anxiety and Depression Scale. Acta Psychiatrica Scandinavica, 67(6), 361–370. https://doi.org/10.1111/j.1600-0447.1983.tb09716.x

13. Items of the Scale